Knome, Inc., a Cambridge, Massachusetts-based provider of human genome interpretation systems and services, closed a $13m financing round.
Backers included current investors.
The company intends to use the funds to expand its genomic services and software systems businesses.
Founded in 2007 and led by CEO Wolfgang Daum, Knome leverages a bioinformatics expertise and proprietary technology platform for researchers, drug developers, and clinicians to determine the genetic basis of human disease and drug response.
It offers an integrated system for the management and interpretation of human genome sequence data, which combines analytical and workflow software, knoSOFT, and a grid computing platform, the knoSYS™100.
The company is now developing its technology into products that support clinical laboratory operations.